Clinical Performance of Cas13a-based Point-of-Care Lateral Flow Assay for Detecting Neisseria gonorrhoeae.

ABSTRACT:

Background

Diagnosis of Neisseria (N.) gonorrhoeae is dependent on nucleic acid amplification testing (NAAT), which is not available in resource-limited settings where the prevalence of infection is highest. Recent advances in molecular diagnostics leveraging the high specificity of CRISPR enzymes can permit field-deployable, point-of-care lateral flow assays. We previously reported on the development and in vitro performance of a lateral flow assay for detecting N. gonorrhoeae. Here we aimed to pair that assay with point-of-care DNA extraction techniques and assess the performance on clinical urine specimens.

Methods

We collected an additional urine specimen among individuals enrolling in an ongoing clinical trial at the Massachusetts General Hospital S

SUBMITTER: Allan-Blitz LT 

PROVIDER: S-EPMC10942539 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature